The Genetic Gap Remains, but Neurons Find Another Way: Antioxidant Reshapes Brain Development in 22q11.2 Deletion Mice

When a chromosomal segment disappears, treatment may not necessarily be limited to trying to restore the original genes. A new study using mice with 22q11.2 deletion syndrome as a model shows that the antioxidant N-acetylcysteine (NAC) can redirect developing neurons to an alternative molecular pathway, improving cell growth, neural connectivity, and cognition-related performance even though the genetic gap remains.

The 22q11.2 deletion reduces the dosage of multiple genes simultaneously. It is one of the strongest known genetic risk factors for schizophrenia and is also associated with autism and a range of cognitive and developmental problems. The research team focused on projection neurons in layers 2 and 3 of the cerebral cortex. These cells connect different cortical regions and, in LgDel deletion mice, are vulnerable to mitochondrial dysfunction and oxidative stress, which consequently restrict axonal and dendritic growth.

The researchers administered NAC to cultured neurons and living mice. The more detailed experimental methods showed that cell cultures received a concentration of 1 millimolar; in the in vivo experiments, NAC was added to drinking water at 900 milligrams per liter beginning on day 14 of the mothers’ pregnancy. The pups continued receiving treatment after birth until samples were collected on postnatal day 6. The treatment improved mitochondrial status, dendritic growth, and neural connectivity, accompanied by improved behavioral performance dependent on the relevant cortical circuits.

The key point is not that the neurons returned to their original state. Transcriptomic analysis showed that NAC neither restored the expression levels of the deleted genes nor broadly returned their downstream targets to wild-type levels; neuronal growth patterns also did not fully return to normal. Instead, the treatment activated another group of genes associated with antioxidant defense, neurite growth, and cellular regulation, creating a state that differed from normal cells but showed improved function.

These findings suggest another therapeutic strategy for complex genetic neurodevelopmental disorders: when a deleted region involves dozens of genes, repairing them individually may not be feasible. Reducing shared cellular stress and mobilizing compensatory gene networks may make it easier to preserve neural circuit function. However, the transcriptional responses to NAC differed substantially between cultured cells and the postnatal mouse cortex, indicating that mechanisms identified in simplified cellular systems cannot be directly regarded as how NAC acts in the living brain.

The current evidence remains limited to cultured cells and mouse models, and the in vivo treatment began during the embryonic stage, far removed from the clinical circumstances of children who have already been born or adults. The study has not demonstrated that NAC can prevent or treat psychiatric or cognitive symptoms in people with a 22q11.2 deletion, nor has it established a dose, timing of intervention, or long-term safety profile suitable for humans. The next step must be to determine which compensatory pathways actually drive the benefits and whether effects can still be produced after the early developmental window has been missed.